[A "newborn" to complete the family of anticholinergics].
Emergence of a new ultra-long acting anticholinergic as glycopyrronium can bring a change of attitude in the life of practitioner. In this article I try to correctly position the new representative of the anticholinergics class, looking at all the evidence in vitro and in viva, benefits, tolerability and safety of this product. Finally, on scientific evidence-based medicine I positioned this product in the new GOLD 2011 classification.